Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Open-Label Study of Efficacy and Recommended Dose of Kovacaine Mist for Anesthetizing Maxillary Teeth

This study has been completed.
Rho, Inc.
Triligent International
Information provided by (Responsible Party):
St. Renatus, LLC Identifier:
First received: November 22, 2011
Last updated: November 2, 2016
Last verified: November 2016
The purpose of this study is to evaluate the efficacy of and recommended dosing regimen for unilateral administration of Kovacaine Mist in inducing pulpal anesthesia of the maxillary teeth for dental procedures.

Condition Intervention Phase
Drug: Kovacaine Mist 0.1 mL x 4 sprays
Drug: Kovacaine Mist 0.2 mL x 2 sprays
Drug: Kovacaine Mist 0.2 mL x 1 spray
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: A Phase II, Single-Site, Open-Label Clinical Trial To Evaluate The Efficacy And Recommended Dosing Regimen Of Kovacaine Mist Administered Unilaterally For Anesthetizing Maxillary Teeth In Healthy Dental Patients

Resource links provided by NLM:

Further study details as provided by St. Renatus, LLC:

Primary Outcome Measures:
  • The Proportion of Subjects Receiving Kovacaine Mist Who do Not Require Rescue Anesthesia During the Operative Dental Procedure [ Time Frame: at 15 minutes, with +10 minute window ]

Secondary Outcome Measures:
  • The Incidence of Subjects Receiving Kovacaine Mist With Changes in Systolic and Diastolic Blood Pressure Exceeding +/- 25% of Preoperative Measurements Values. [ Time Frame: 60 minutes ]
  • The Proportion of Subjects Giving a Positive Response to Evaluation Question for Subjective Numbness Assessment (SNA) After the Procedure is Completed. [ Time Frame: 60 minutes ]
  • Naris Examination [ Time Frame: 60 minutes post drug administration ]
    Number of patients with an abnormal naris examination finding.

Enrollment: 30
Study Start Date: January 2012
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Kovacaine Mist 0.1 mL x 4 sprays
Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
Drug: Kovacaine Mist 0.1 mL x 4 sprays
Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
Other Name: Tetracaine HCl 3% and HCl 0.05%
Experimental: Kovacaine Mist 0.2 mL x 2 sprays
Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
Drug: Kovacaine Mist 0.2 mL x 2 sprays
Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
Other Name: Tetracaine HCl 3% and HCl 0.05%
Experimental: Kovacaine Mist, 0.2 mL x 1 spray
Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
Drug: Kovacaine Mist 0.2 mL x 1 spray
Dose = 1 intranasal spray of study drug
Other Name: Tetracaine HCl 3% and HCl 0.05%

Detailed Description:
This is a Phase II single-center, open-label clinical trial with three dosing regimens, designed to determine the efficacy and optimal dose of the Kovacaine Mist intranasal delivery system for inducing pulpal anesthesia of maxillary teeth numbers 4-13 (maxillary right second premolar to maxillary left second premolar). Kovacaine will be administered intranasally on the same side of the midline as the tooth on which the procedure will be performed in three dosing cohorts [four 100 μL, two 200 μL, or one 200 μL spray(s)] of 10 subjects each. The first cohort receiving 4 sprays will be completed before initiating study of the remaining two cohorts, which will be treated using a randomized, parallel-group design. Administration: Subjects in the 4- and 2-spray cohorts will be administered the same total dose of 12 mg tetracaine HCl/0.2 mg oxymetazoline HCl. The 4-spray cohort will be treated with a sequence of four 100-μL sprays at intervals of 4 minutes. The 2-spray cohort will be treated with a sequence of two 200 μL sprays 4 minutes apart. The 1-spray cohort will be administered one 200 μL spray, a total dose of 6 mg tetracaine HCl/0.1 mg oxymetazoline HCl, which is half the dose of the 2-spray cohort. Rescue: If the study drug does not provide sufficient anesthesia to allow for completion of the dental procedure, a rescue injection of articaine will be administered.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female subjects who are 18 years of age or older;
  • requiring an operative restorative procedure on a single maxillary tooth with no evidence of pulpal pathology requiring local anesthesia;
  • having normal lip, nose, eyelid, and cheek sensations;
  • able to understand and sign the informed consent document, communicate with the investigators, and understand and comply with the requirements of the protocol;
  • having patency of naris on same side of head as tooth requiring the dental procedure.

Exclusion Criteria:

  • Inadequately controlled hypertension (blood pressures greater than 150/90) or untreated coronary heart disease;
  • inadequately controlled thyroid disease including Hashimoto's thyroiditis and partial thyroidectomy;
  • having frequent nose bleeds (10 per month);
  • having received dental care requiring a local anesthetic within the last 24 hours;
  • history of allergy to or intolerance of tetracaine, benzyl alcohol, benzocaine, other ester local anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreens);
  • history of allergy or hypersensitivity to articaine, oxymetazoline, epinephrine, or sulfite preservatives; history of taking a monoamine oxidase inhibitor within the past 3 weeks;
  • are nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females will be required to take a urine pregnancy test on the day of but prior to study drug administration to rule out pregnancy);
  • having used any investigational drug and/or participated in any clinical research trial within 30 days of baseline
  • enlarged prostate
  • narrow angle glaucoma
  • use of oxymetazoline or phenylephrine nasal spray or oral decongestant on the day of the study
  • congenital or idiopathic methemoglobinemia
  • diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01479517

United States, Colorado
Rock Dental Clinic
Colorado Springs, Colorado, United States, 80919
Sponsors and Collaborators
St. Renatus, LLC
Rho, Inc.
Triligent International
Principal Investigator: Christina Sletten, DDS Rock Dental Clinic
  More Information

Responsible Party: St. Renatus, LLC Identifier: NCT01479517     History of Changes
Other Study ID Numbers: SR 2-05
Study First Received: November 22, 2011
Results First Received: November 2, 2016
Last Updated: November 2, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by St. Renatus, LLC:
dental procedure

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on April 28, 2017